By Andrew M. Kohlmetz
•
27 Apr, 2020
The nation-wide COVID-19 health crisis has brought seemingly endless stories about people hoarding, and selling or reselling personal protective equipment (“PPE”) at huge price mark-ups. This type of hoarding or profiteering is no longer subject to the risk of social media and moral shaming. It can be criminal, and the FDA’s Office of Criminal Investigations (“FDA-OCI”)is aggressively pursuing people and business engaged in the distribution, sale and resale of PPE. On March 25, 2020, the federal Department of Health and Humans Services (“HHS”) by notice in the Code of Federal Regulations, designated a wide selection of PPE as “scarce materials or materials the supply of which would be threatened by accumulation in excess of reasonable demands of business, personal, or home consumption, or for the purpose of resale at prices in excess of prevailing market prices.” 85 Fed. Reg. 17592 . This designation includes many types of equipment including face masks, respirators, gowns, gloves, disinfecting supplies etc. The designation brings people or entities in the business of purchasing, selling or otherwise distributing PPE under the provisions of the federal Defense Production Act. (“DPA”) Under section 4512 of the DPA it is unlawful for anyone to “accumulate (1) in excess of the reasonable demands of business, personal, or home consumption, or (2) for the purpose of resale at prices in excess of prevailing market prices, materials which have been designated by the President as scarce materials or materials the supply of which would be threatened by such accumulation.” Violation of this section of the DPA is a class A misdemeanor and carries a potential sentence of up to one year in jail and a fine of $10,000. 50 U.S.C. §§ 4152, 4153 . The FDA-OCI and other federal civil and law enforcement agencies are actively looking for and investigating persons involved in the purchasing, selling or otherwise distributing PPE. In some cases it has been discovered that certain PPE was counterfeit, or rebranded and marketed for originally unauthorized – even patently false purposes such as a “COVID-19 cure” or “effective anti-viral protection.” The making of any such false or misleading claims or the sale of counterfeit and/or expired products could also give rise to far more serious federal wire and or mail fraud charges. If you are engaged in the purchase, distribution or sale of PPE such as N95 respirators, face shields, surgical masks, or other COVID-19 related-PPE, contact Andrew M. Kohlmetz , a federal criminal defense attorney familiar with the DPA and the recent COVID-19-related regulations, to discuss how to limit any potential liability. By the time the FDA-OCI reaches out, it might be too late.